Editorial Comment: Leave no lymph nodes behind!

Abstract

Listen

Translate article

pathological noninvasiveness in peripheral clinical IA lung cancer ( Japan Clinical Oncology Group 0201). J Thorac Oncol 2011;6:751–6. [13] Goldstraw P. Report on the international workshop on intrathoracic staging. London, October 1996. Lung Cancer 1997;18:107–11. [14] Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura H. Radiologic classification of small adenocarcinoma of the lung: radiologicpathologic correlation and its prognostic impact. Ann Thorac Surg 2006; 81:413–9. [15] Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141:662–70. [16] Izbicki JR, Passlick B, Pantel K, Pichlmeier U, Hosch SB, Karg O et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg 1998;227:138–44. [17] Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer 2002;36:1–6. [18] Takizawa T, Terashima M, Koike T, Akamatsu H, Kurita Y, Yokoyama A. Mediastinal lymph node metastasis in patients with clinical stage I peripheral non-small-cell lung cancer. J Thorac Cardiovasc Surg 1997;113: 248–52. [19] Prenzel KL, Monig SP, Sinning JM, Baldus SE, Gutschow CA, Grass G et al. Role of skip metastasis to mediastinal lymph nodes in non-small cell lung cancer. J Surg Oncol 2003;82:256–60. [20] Misthos P, Sepsas E, Athanassiadi K, Kakaris S, Skottis I. Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardiothorac Surg 2004;25:502–8. [21] Watanabe S, Suzuki K, Asamura H. Superior and basal segment lung cancers in the lower lobe have different lymph node metastatic pathways and prognosis. Ann Thorac Surg 2008;85:1026–31. [22] Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589–97. [23] Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552–9. [24] Satoh Y, Okumura S, Nakagawa K, Horiike A, Ohyanagi F, Nishio M et al. Postoperative ischemic change in bronchial stumps after primary lung cancer resection. Eur J Cardiothorac Surg 2006;30:172–6.